Analysis of two-gene signatures and related drugs in small-cell lung cancer by bioinformatics
Small-cell lung cancer (SCLC) has a poor prognosis and can be diagnosed with systemic metastases. Nevertheless, the molecular mechanisms underlying the development of SCLC are unclear, requiring further investigation. The current research aims to identify relevant biomarkers and available drugs to t...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2023-10-01
|
| Series: | Open Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/med-2023-0806 |
| _version_ | 1797660962587672576 |
|---|---|
| author | Li Yi Zhou Xiwen Lyu Zhi |
| author_facet | Li Yi Zhou Xiwen Lyu Zhi |
| author_sort | Li Yi |
| collection | DOAJ |
| description | Small-cell lung cancer (SCLC) has a poor prognosis and can be diagnosed with systemic metastases. Nevertheless, the molecular mechanisms underlying the development of SCLC are unclear, requiring further investigation. The current research aims to identify relevant biomarkers and available drugs to treat SCLC. The bioinformatics analysis comprised three Gene Expression Omnibus datasets (including GSE2149507, GSE6044, and GSE30219). Using the limma R package, we discovered differentially expressed genes (DEGs) in the current work. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were made by adopting the DAVID website. The DEG protein–protein interaction network was built based on the Search Tool for the Retrieval of Interacting Genes/Proteins website and visualized using the CytoHubba plugin in Cytoscape, aiming to screen the top ten hub genes. Quantitative real-time polymerase chain reaction was adopted for verifying the level of the top ten hub genes. Finally, the potential drugs were screened and identified using the QuartataWeb database. Totally 195 upregulated and 167 downregulated DEGs were determined. The ten hub genes were NCAPG, BUB1B, TOP2A, CCNA2, NUSAP1, UBE2C, AURKB, RRM2, CDK1, and KIF11. Ten FDA-approved drugs were screened. Finally, two genes and related drugs screened could be the prospective drug targets for SCLC treatment. |
| first_indexed | 2024-03-11T18:38:27Z |
| format | Article |
| id | doaj.art-1026064da3f74376b57a829510427d0f |
| institution | Directory Open Access Journal |
| issn | 2391-5463 |
| language | English |
| last_indexed | 2024-03-11T18:38:27Z |
| publishDate | 2023-10-01 |
| publisher | De Gruyter |
| record_format | Article |
| series | Open Medicine |
| spelling | doaj.art-1026064da3f74376b57a829510427d0f2023-10-12T14:07:02ZengDe GruyterOpen Medicine2391-54632023-10-011812094910.1515/med-2023-0806Analysis of two-gene signatures and related drugs in small-cell lung cancer by bioinformaticsLi Yi0Zhou Xiwen1Lyu Zhi2The School of Clinical Medicine, Fujian Medical University, Fuzhou, ChinaMedical College, Shantou University, Shantou, ChinaThe School of Clinical Medicine, Fujian Medical University, Fuzhou, ChinaSmall-cell lung cancer (SCLC) has a poor prognosis and can be diagnosed with systemic metastases. Nevertheless, the molecular mechanisms underlying the development of SCLC are unclear, requiring further investigation. The current research aims to identify relevant biomarkers and available drugs to treat SCLC. The bioinformatics analysis comprised three Gene Expression Omnibus datasets (including GSE2149507, GSE6044, and GSE30219). Using the limma R package, we discovered differentially expressed genes (DEGs) in the current work. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were made by adopting the DAVID website. The DEG protein–protein interaction network was built based on the Search Tool for the Retrieval of Interacting Genes/Proteins website and visualized using the CytoHubba plugin in Cytoscape, aiming to screen the top ten hub genes. Quantitative real-time polymerase chain reaction was adopted for verifying the level of the top ten hub genes. Finally, the potential drugs were screened and identified using the QuartataWeb database. Totally 195 upregulated and 167 downregulated DEGs were determined. The ten hub genes were NCAPG, BUB1B, TOP2A, CCNA2, NUSAP1, UBE2C, AURKB, RRM2, CDK1, and KIF11. Ten FDA-approved drugs were screened. Finally, two genes and related drugs screened could be the prospective drug targets for SCLC treatment.https://doi.org/10.1515/med-2023-0806bioinformaticsbiomarkerssmall cell lung cancerindividualized diagnosistargeted drugs |
| spellingShingle | Li Yi Zhou Xiwen Lyu Zhi Analysis of two-gene signatures and related drugs in small-cell lung cancer by bioinformatics Open Medicine bioinformatics biomarkers small cell lung cancer individualized diagnosis targeted drugs |
| title | Analysis of two-gene signatures and related drugs in small-cell lung cancer by bioinformatics |
| title_full | Analysis of two-gene signatures and related drugs in small-cell lung cancer by bioinformatics |
| title_fullStr | Analysis of two-gene signatures and related drugs in small-cell lung cancer by bioinformatics |
| title_full_unstemmed | Analysis of two-gene signatures and related drugs in small-cell lung cancer by bioinformatics |
| title_short | Analysis of two-gene signatures and related drugs in small-cell lung cancer by bioinformatics |
| title_sort | analysis of two gene signatures and related drugs in small cell lung cancer by bioinformatics |
| topic | bioinformatics biomarkers small cell lung cancer individualized diagnosis targeted drugs |
| url | https://doi.org/10.1515/med-2023-0806 |
| work_keys_str_mv | AT liyi analysisoftwogenesignaturesandrelateddrugsinsmallcelllungcancerbybioinformatics AT zhouxiwen analysisoftwogenesignaturesandrelateddrugsinsmallcelllungcancerbybioinformatics AT lyuzhi analysisoftwogenesignaturesandrelateddrugsinsmallcelllungcancerbybioinformatics |